PROactive study.
作者信息
Goldstein Mark R
出版信息
Lancet. 2006 Jan 7;367(9504):23; author reply 26-7. doi: 10.1016/S0140-6736(06)67910-5.
Abstract
摘要
相似文献
1
PROactive study.
Lancet. 2006 Jan 7;367(9504):23; author reply 26-7. doi: 10.1016/S0140-6736(06)67910-5.
2
Pioglitazone and bladder cancer: the pros and cons.
J Assoc Physicians India. 2012 Jan;60:72-3.
3
The cage in search of a bird.
J Assoc Physicians India. 2012 Jan;60:74-5.
4
Pioglitazone for diabetes prevention.
N Engl J Med. 2011 Jul 14;365(2):183; author reply 183-4. doi: 10.1056/NEJMc1104572.
5
Possible link of pioglitazone with bladder cancer in Japanese patients with type 2 diabetes.
Diabetes Res Clin Pract. 2013 Feb;99(2):e21-3. doi: 10.1016/j.diabres.2012.11.013. Epub 2012 Dec 7.
6
Pioglitazone and the risk of bladder cancer.
BMJ. 2012 May 30;344:e3500. doi: 10.1136/bmj.e3500.
7
Balancing the risks and benefits for pioglitazone in type 2 diabetes.
Diabetes Res Clin Pract. 2012 Oct;98(1):1-2. doi: 10.1016/j.diabres.2012.08.005. Epub 2012 Sep 7.
8
[Pioglitazone and the risk of bladder cancer].
Nihon Rinsho. 2016 Apr;74 Suppl 2:442-6.
9
Pioglitazone Use and Risk of Bladder Cancer.
JAMA. 2015 Dec 15;314(23):2568. doi: 10.1001/jama.2015.13909.
10
Pioglitazone Use and Risk of Bladder Cancer.
JAMA. 2015 Dec 15;314(23):2567-8. doi: 10.1001/jama.2015.13912.
引用本文的文献
1
Intensive glycaemic control and cancer risk in type 2 diabetes: a meta-analysis of major trials.
Diabetologia. 2011 Jan;54(1):25-31. doi: 10.1007/s00125-010-1933-3. Epub 2010 Oct 20.
2
Glucose-lowering therapies and cancer risk: the trials and tribulations of trials and observations.
Diabetologia. 2010 Sep;53(9):1823-6. doi: 10.1007/s00125-010-1780-2. Epub 2010 Jun 4.
Zotero 插件